AAFMAA Wealth Management & Trust LLC Has $2.46 Million Stock Position in Boston Scientific Co. (NYSE:BSX)

AAFMAA Wealth Management & Trust LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 17.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,349 shares of the medical equipment provider's stock after selling 5,289 shares during the period. Boston Scientific accounts for 1.1% of AAFMAA Wealth Management & Trust LLC's holdings, making the stock its 19th biggest position. AAFMAA Wealth Management & Trust LLC's holdings in Boston Scientific were worth $2,456,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently made changes to their positions in the company. Norges Bank bought a new stake in Boston Scientific during the fourth quarter worth $1,762,522,000. Capital World Investors increased its stake in shares of Boston Scientific by 28.7% during the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock worth $2,492,041,000 after purchasing an additional 6,216,199 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after purchasing an additional 3,344,571 shares during the period. GAMMA Investing LLC lifted its stake in Boston Scientific by 11,720.3% in the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock valued at $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. Finally, Axiom Investors LLC DE grew its holdings in Boston Scientific by 208.2% during the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after purchasing an additional 2,535,007 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Robert W. Baird upped their price objective on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Needham & Company LLC reissued a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. UBS Group raised their price target on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 7th. BTIG Research reaffirmed a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Twenty-one analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $116.00.

Boston Scientific Price Performance

Boston Scientific stock opened at $102.04 on Friday. The stock's fifty day moving average price is $100.49 and its two-hundred day moving average price is $98.37. The firm has a market cap of $150.96 billion, a PE ratio of 81.63, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter last year, the business earned $0.56 earnings per share. Boston Scientific's revenue was up 20.9% on a year-over-year basis. As a group, research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president now owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now directly owns 1,535,706 shares in the company, valued at $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 411,970 shares of company stock valued at $42,406,693. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.